| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | TRIM25; EFP; RNF147; ZNF147; E3 ubiquitin/ISG15 ligase TRIM25; Estrogen-responsive finger protein; RING finger protein 147; Tripartite motif-containing protein 25; Ubiquitin/ISG15-conjugating enzyme TRIM25; Zinc finger protein 147 |
| Entrez GeneID | 7706 |
| WB Predicted band size | Calculated MW: 71 kDa; Observed MW: 71 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human TRIM25 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于TRIM25抗体的3篇文献示例(文献信息为模拟概括，仅供参考)：
---
1. **"TRIM25 mediates RIG-I ubiquitination and antiviral immune signaling"**
*作者：Gack MU et al.*
**摘要**：该研究揭示了TRIM25通过其E3泛素连接酶活性，介导RIG-I的K63位泛素化修饰，从而激活Ⅰ型干扰素信号通路，对抗RNA病毒感染。研究中利用TRIM25抗体验证其与RIG-I的相互作用及亚细胞定位。
---
2. **"TRIM25 promotes cell proliferation and tumorigenesis in breast cancer"**
*作者：Zhang Y et al.*
**摘要**：本文发现TRIM25在乳腺癌组织中高表达，通过泛素化降解抑癌蛋白p53促进肿瘤生长。实验使用TRIM25抗体进行免疫组化分析，证实其表达与患者预后不良相关。
---
3. **"Structural basis of TRIM25 E3 ubiquitin ligase activity"**
*作者：Dickson C et al.*
**摘要**：该研究解析了TRIM25的RING结构域晶体结构，阐明其催化泛素转移的分子机制。通过TRIM25抗体共免疫沉淀实验，验证了其与E2泛素结合酶的功能性互作。
---
4. **"TRIM25 suppresses Zika virus replication by targeting viral NS3 protein"**
*作者：Suzuki T et al.*
**摘要**：研究发现TRIM25通过直接结合寨卡病毒NS3蛋白并介导其泛素化降解，抑制病毒复制。Western blot和免疫荧光实验使用TRIM25抗体证实其在感染过程中的调控作用。
---
(注：以上文献标题与摘要内容为领域典型研究方向的人工概括，实际引用时请核实具体文献信息。)
TRIM25 (Tripartite Motif-containing protein 25), also known as E3 ubiquitin-protein ligase TRIM25. is a member of the TRIM family characterized by its conserved RING finger, B-box, and coiled-coil domains. It plays a multifaceted role in cellular processes, including innate immunity, antiviral defense, and cancer progression. TRIM25 gained prominence for its role in ubiquitinating retinoic acid-inducible gene I (RIG-I), a critical step in activating the RIG-I signaling pathway to induce type I interferons during viral infections, particularly against RNA viruses like influenza. Beyond immunity, TRIM25 exhibits dual roles in cancer, acting as either an oncogene or tumor suppressor depending on context. For example, it promotes breast and ovarian cancer progression by stabilizing oncoproteins (e.g., 14-3-3σ) or degrading tumor suppressors (e.g, ZBRK1), while its downregulation in hepatocellular carcinoma correlates with poor prognosis.
TRIM25 antibodies are essential tools for studying its expression, post-translational modifications, and interactions. These antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to investigate TRIM25's regulatory mechanisms in disease models. Due to splice variants and post-translational modifications, selecting validated antibodies with high specificity is crucial. Many studies employ knockout cell lines to confirm antibody specificity. Additionally, TRIM25 antibodies have therapeutic implications, as emerging research explores targeting TRIM25-related pathways to modulate immune responses or cancer growth. Their utility spans virology, immunology, and oncology, making them vital for dissecting TRIM25's complex roles in health and disease.
×
